<qa>  What is the maximum dose of a statin?: Patients with hyperlipidemia who sign consent and who are currently at maximum tolerated dose of a statin and are not meeting NCEP ATPIII treatment goals for LDL cholesterol are enrolled in 12-week open label, prospective trial. Patients are randomized into one of three groups to receive ezetimibe, niacin, or colestipol in addition to current statin therapy. Patients are titrated as tolerated to therapeutic doses of study medications ezetimibe 10mgday, niacin 1500mgday, and colestipol 20gmday. At baseline, informed consent; a laboratory admission profile Chem20; weight; height; blood pressure; concomitant medications; cholesterol medication history; and grapefruit juice consumption data are gathered. At weeks 6 and 12, patients have their cholesterol panels and liver function tests assessed. Patients are also interviewed regarding side effects including rhabdomyolysis, tolerance, changes in concomitant medications, and grapefruit juice consumption, along with weight and blood pressure measurements. 